SMTL ID : 8bm2.1 (1 other biounit)

Crystal structure of JAK2 JH1 in complex with gandotinib

Coordinates

PDB Format Compare

Method

X-RAY DIFFRACTION 1.50 Å

Oligo State

monomer

Ligands

1 x QQC: 3-[(4-chloranyl-2-fluoranyl-phenyl)methyl]-2-methyl-~{N}-(5-methyl-1~{H}-pyrazol-3-yl)-8-(morpholin-4-ylmethyl)imidazo[1,2-b]pyridazin-6-amine(Non-covalent)

QQC.1: 23 residues within 4Å: Chain A: Q.38, L.40, G.41, F.45, V.48, M.50, A.65, V.96, M.114, E.115, Y.116, L.117, P.118, Y.119, G.120, S.121, D.124, K.128, R.165, N.166, L.168, G.178, D.179 10 PLIP interactions: 10 interactions with chain A Hydrophobic interactions: A:F.45, A:Y.116, A:L.168 Hydrogen bonds: A:E.115, A:L.117, A:L.117 Water bridges: A:Q.38, A:D.124, A:D.124 pi-Stacking: A:F.45

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Miao, Y. et al., Structural basis for JAK2 inhibition by clinical stage inhibitors. To Be Published

Release Date

2023-11-22

Peptides

Tyrosine-protein kinase JAK2: A

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

Tyrosine-protein kinase JAK2

Related Entries With Identical Sequence